Update on primary HPV screening for cervical cancer prevention

Rizzo, Alicia N.; Feldman, Sarah

doi:10.1016/j.currproblcancer.2018.06.013

Cited by 25 publications

(27 citation statements)

References 53 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Meta-analysis (PCR-based) of worldwide studies showed that HPV in patients with a negative Pap test is 10% [41]. The presence of HR HPV in negative cervical smears highlights the need for an active screening program [42]. A patient ≥30 years with a positive HPV and negative cytology is at higher risk of developing cervical cancer.…”

Section: Discussion/conclusionmentioning

confidence: 99%

Correlation of High-Risk HPV Genotypes with Pap Test Findings: A Retrospective Study in Eastern Province, Saudi Arabia

et al. 2020

View full text Add to dashboard Cite

Introduction: High-risk human papillomavirus (HR HPV) is found to be responsible for 4.5% of cancer in general, primarily cervical cancer. We aim here to highlight the prevalence and genotypes of HR HPV and correlate its association with Pap tests’ results, which are still not well known in the Eastern Province of Saudi Arabia. Methods: Over 7 years (2013–2019), the results of 164 Saudi women coinvestigated for HR HPV along with Pap tests were collected from the archive of King Fahd University Hospital. Only women who had atypical squamous cells of undetermined significance (ASCUS) on the Pap test and those at elevated risk of infection were cotested for HR HPV; otherwise, the Pap test was the only screening modality for cervical cancer. Data were organized and statistically analyzed using IBM SPSS v26. Results: Out of 164 Saudi women, 14.5% (n = 24/164) showed positive results for HR HPV (8 patients had HPV16 and 2 had both HPV16 and HPV18/45, while the remaining 14 had other HR HPV); among them, 41.5% (n = 10/24) had an abnormal Pap test (5 ASCUS and 5 LSIL), while 58.5% (n = 14/24) had a negative Pap test. On the other hand, 21% (n = 35/164) of patients, in the study, had an abnormal Pap test (24 ASCUS, 8 low-grade squamous intraepithelial lesion [LSIL], and 3 atypical glandular cell [AGC]). In 80% (n = 19/24) of ASCUS cases, HR HPV was not detected; however, 20% (n = 5/24) were positive for other HR HPV. Concerning LSIL cases, 62.5% (n = 5/8) were positive for HR HPV (1 case showed HPV16 and HPV18/45, 2 cases showed HPV16, and 2 cases showed other HR HPV), while in the remaining 37.5% (n = 3/8) LSIL cases, HR HPV was negative; similarly, all AGC cases were negative for HR HPV. Statistical analysis showed a significant correlation between HPV status and Pap test findings (p value <0.001). Discussion/Conclusion: HR HPV frequency and genotype distribution, in this study, might reflect a different regional infection pattern. The high association of HR HPV with negative cytology emphasizes the need to add the HR HPV test to screening modalities of cervix cancer.

show abstract

Section: Discussion/conclusionmentioning

confidence: 99%

Correlation of High-Risk HPV Genotypes with Pap Test Findings: A Retrospective Study in Eastern Province, Saudi Arabia

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Due to the importance of viral prevalence closed alongside the geographical variability, different associations all over the world have supported the use of DNA HPV testing, with high sensibility and specificity, especially in women older than 30 years of age and in patients with abnormal cytology. 20…”

Section: Discussionmentioning

confidence: 99%

“…Although the Pap smear test has improved the detection of CC, there are some disadvantages, for example, high specificity but low sensitivity, therefore it is important to develop more sensitive and specific techniques to improve prevention algorithms. 20…”

Section: Introductionmentioning

confidence: 99%

Prevalence and correlation of human papillomavirus genotypes with clinical factors in cervical samples from Mexican women

Hernández‐Rosas

Orozco-Hernández

Maza-Sánchez³

et al. 2020

Exp Biol Med (Maywood)

View full text Add to dashboard Cite

In the last decade, the inclusion of HPV DNA testing in cervical cancer screening has provided one of the best strategies for the prevention and timely detection of HPV. We conducted a high-throughput HPV genotyping study based on MALDI-TOF mass spectrometry to determine the prevalence of 24 HPV genotypes, including oncogenic genotypes, in Mexican women and correlated the results with cytological findings and clinical variables. We likewise identified the risk factors in patients with the HPV infection. Our study included 1000 women from Sonora, Mexico, who participated in cervical cancer screening campaigns and who underwent a Pap smear and HPV DNA test. The results showed that the overall prevalence of HPV was 27.2%, 18.5% with single, and 8.7% multiple infections. The low-risk HPV genotype 6 (8.5%) and oncogenic genotypes 31 (8.1%) and 53 (4.4%) were the most prevalent in the study population. The number of lifetime sexual partners, previous STIs, and age at first intercourse was significantly associated with HPV infection ( P ≤ 0.05). Smoking (OR = 1.5609; 95% IC 1.062–2.292) and more than three lifetime sexual partners (OR = 1.609; 95% IC = 1.124–2.303) represented risk factors for HPV infection. Cytological abnormalities were found in 3.4% of the HPV-positive samples. CIN 1–3 occurred in 0.6% of high-risk HPV cases. In general, the prevalence of the HPV genotypes is high in Mexican women with normal cytological findings. This issue highlights the importance of HPV research in seemingly healthy women and could help guide screening strategies for cervical cancer prevention in Mexico. Impact statement We are submitting data regarding the prevalence and type distribution of the HPV infection and the risk factors associated with it, which may provide a valuable reference to reinforce screening strategies, and to maintain HPV genotype surveillance in Mexico. We discuss the overall prevalence of HPV infection as detected in normal cytological samples stratified by age, different types of infection, and oncogenic capacity. One of the most important findings was that common HPV genotypes detected in healthy women were the genotype numbers: 6, 31, 16, and 56, likewise, smoking and having a history of more than three sexual partners over their lifetime, represented the main risk factors in this study. Furthermore, we found a low frequency of cytological abnormalities and CIN 1–3 in women with HR-HPV.

show abstract

“…Dintre tulpinile de HPV, cele mai des identificate și corelate cu apariția patologiei descrise sunt HPV -16 (50%) și HPV -18 (10%). Totuși, există încă un număr semnificativ de alte tulpini, împărțite în două clase: cu risc crescut să ducă la apariția cancerului și cu risc scăzut (Rizzo A.E., 2018). Factorii de risc descoperiți (Johnson C.A., 2019) sunt stilul de viață (numărul de parteneri sexuali, numărul de sarcini, primul contact sexual prea devreme/ întârziat etc.…”

Section: Introducereunclassified

Evoluția nanoparticulelor în tratamentul cancerului de col uterin – de la transportor la nanoreactor enzimatic

Necula¹,

Brașov²

2019

JMB

View full text Add to dashboard Cite

Since the 1960s, when Richard Feynman talked for the first time about nanoparticles, scientists have worked to improve nanomedicine. As part of their effort, scientists have done new studies in the pharmacology and oncology fields and have found new uses for particles smaller than 100nm. For the first time in the treatment of cervical neoplasia a nanoparticle was used for drug delivery (DD). Our understanding of nanoparticles has evolved over the years providing new ideas such as using them in cervical cancer diagnosis, e.g. as biosensors. Lately, the combination between a particle and an enzyme or the enzyme's substrate was considered, enhancing significantly their performance. Enzymatic nanoreactors may bring the treatment of cervical cancer to a new stage of evolution. Although in vivo tests (on xenograft models) of certain enzymatic nanotechnology are promising, further studies are required to support and to improve the findings available at the moment. Rezumat:Din 1960, de la discursul lui Richard Feynman, când au fost puse bazele nanomedicinei, nanoparticulele au cunoscut multe schimbări în evoluția lor. Datorită dezvoltării farmacologiei și a descoperirilor în sfera oncologiei, au apărut noi roluri pentru particulele cu dimensiuni mai mici de 100nm. Astfel, în patologii precum neoplazia de col uterin nanoparticulele au apărut inițial pentru transportul substanțelor farmacologic active. Ulterior, au fost utilizate pentru detecția celulelor tumorale. Un pas major în evoluția nanomedicinei în cancerul de col uterin este asocierea nanoparticulelor cu diverse enzime sau substraturi enzimatice, apărând astfel nanoreactoarele enzimatice. Acestea au un viitor promițător în tratamentul cancerului de col uterin. Testele in vivo au demonstrat o penetranță bună la nivelul masei tumorale și o reducere semnificativă a acesteia în urma tratamentului.

show abstract

Update on primary HPV screening for cervical cancer prevention

Cited by 25 publications

References 53 publications

Correlation of High-Risk HPV Genotypes with Pap Test Findings: A Retrospective Study in Eastern Province, Saudi Arabia

Correlation of High-Risk HPV Genotypes with Pap Test Findings: A Retrospective Study in Eastern Province, Saudi Arabia

Prevalence and correlation of human papillomavirus genotypes with clinical factors in cervical samples from Mexican women

Evoluția nanoparticulelor în tratamentul cancerului de col uterin – de la transportor la nanoreactor enzimatic

Contact Info

Product

Resources

About